bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract 5656: Anticentromere Antibody Increases ICAM-1 Expression and Monocyte Adhesion in Pulmonary Endothelial Cells: Implications for Scleroderma-Associated Pulmonary Hypertension
Authors: Nakhla Shirley , Ilsar Rahn , Heather Alison K , Celermajer David S 
Published: April 2024

BACKGROUND: Scleroderma is characterized by the presence of high circulating levels of anticentromere antibody (ACA) and is commonly complicated by pulmonary hypertension (PHT). We hypothesized that ACA may alter pulmonary endothelial cell function.
METHODS: Human pulmonary microvascular endothelial cells (HPMvECs) were treated with ACA (0.25 – 1.0 mg/mL, equivalent to serum titers of 1:320 – 1:2560) and IgG controls. Monocyte adhesion to HPMvECs was measured by automated cell count and cell adhesion molecule expression (ICAM-1 and VCAM-1) was assessed by flow cytometry (protein) and RT-PCR (mRNA). Promoter activity was assessed by luciferase reporter vector in HPMvECs and human umbilical vein endothelial cells (HUVECs). ACA uptake into HPMvECs was assessed by fluorescent microscopy.

RESULTS: Fluorescently labeled ACA was shown to penetrate HPMvECs within 10 min. ACA increased ICAM-1 protein levels in a dose-dependent manner (118±11, 132±8 & 162±7% increase vs control (100%) for 0.50, 0.75 & 1.0 mg/mL respectively, P < 0.0001, n=5; Fig

). No effect was observed for VCAM-1. ICAM-1 increases were associated with enhanced monocyte adhesion to endothelial cells (211±9%, 1.0 mg/mL vs control, P < 0.0001, n=3). ICAM-1 mRNA levels were markedly increased by ACA (745±113%, 1.0 mg/mL vs control, P < 0.0001, n=4). ACA did not affect ICAM-1 mRNA stability but increased ICAM-1 promoter activity (136±9% & 148±12%, 1.0 mg/mL vs control for HPMvECs & HUVECs respectively, P < 0.01, n=3).

CONCLUSION: ACA increases HPMvECs ICAM-1 expression and monocyte cell adhesion. These findings may implicate a role for ACA in the development of PHT in scleroderma.
Abstract 5794: Clinical Risk Factors to Predict Deep Venous Thrombosis Post Endovenous Laser Ablation of Saphenous Veins
Authors: Chi Yung-Wei , Ali Lobna , Woods T. Cooper 
Published: April 2024

Introduction: Endovenous laser ablation of saphenous veins is an alternative to standard surgical vein stripping for the treatment of symptomatic varicose veins. Deep venous thrombosis (DVT) has been reported as a complication of such procedure with a rate of 1 to 5 %. Clinical risk factors to predict DVT post endovenous laser ablation are not well established.
Hypothesis: To establish clinical risk factors to predict DVT post endovenous laser ablation.
Method: Three hundred sixty consecutive patients who underwent endovenous laser ablation of saphenous veins were followed. Duplex ultrasound was performed within 1 week of the index procedure. DVT was defined as evidence of non-compressibility involving the sapheno-femoral, sapheno-popliteal junctions or any of the deep veins. Comparison between those with and without DVT was performed using step-wise logistic regression (SAS, SAS Institute, Cary, NC) to measure the correlation between continuous and categorical variables. The continuous variables included age, weight, glomerular filtration rate, distance of laser ablation, total energy used and the categorical variables included gender, diabetes mellitus, hypertension, hyperlipidemia, prior stroke, superficial venous thrombosis (SVT), DVT, coronary artery disease, peripheral arterial disease, and pulmonary embolism. Additional iterations were performed to determine the predictive power of various age thresholds. A p value < 0.05 was accepted as representing a significant difference.
Result: Nineteen DVTs were found on follow up ultrasound. Eighteen cases involved either the sapheno-femoral or sapheno-popliteal junctions. Only one case involved the deep venous system. Age > 66 (p = 0.007), female gender (p = 0.048) and prior history of SVT (p = 0.002) were associated with increased risk of DVT post endovenous laser ablation.
Conclusion: Age > 66, female gender and history of prior SVT are risk factors to predict DVT post endovenous laser ablation.

Clinical Risk Factors to Predict DVT Post Endovenous Laser Ablation
Abstract 5800: Angiopoietin-2 Induced Left Ventricular Hypertrophy is Reduced by AAV-mediated Angiopoietin-1 Overexpression
Authors: Horstkotte Jan , Schwab Claudia , Ziegler Tilman , Schroeder Melanie , Hinkel Rabea , Kieu Cuong , Deutsch Urban , Kupatt Christian 
Published: April 2024

Angiopoietin-2 (Ang-2), a co-factor in postnatal angiogenesis interacting at the endothelial Tie-2 receptor, is a potential target for therapeutic angiogenesis. Though antagonistic functions of Ang-2 and Angiopoietin-1 (Ang-1) have been described, the impact of long lasting Ang-2 expression on cardiac function has not been characterized. Here we analysed the impact of chronic Ang-2 overexpression and interaction with Ang-1 on myocardial morphology and function using a AAV2.9-vector overexpressing Ang-1 (rAAV-Ang-1).
Methods: For this purpose conditional Ang-2 overexpressing mice (Tet-off transgenic mice, under control of Tie2-promoter = Ang2-tg) were established and analyzed by echocardiography, non-invasive heart rate (HR), mean arterial pressure (MAP) and invasive catheterization.
Results: Ang2-tg mice displayed a significant cardiac dilation from 12 wks to 24 wks of age (LV-EDD: Ang2-tg: 0,47±0,02cm, control: 0,39±0,01cm, n=18). Application of doxycycline (Dox) or transfection of rAAV-Ang-1 (Ang2-tg+rAAV-Ang1) reversed the phenotype almost entirely (Ang2-tg+Dox: 0,43±0,01cm, Ang2-tg+rAAV-Ang1: 0,40±0,02cm, control 0,40±0,01cm), while absence of treatment resulted in progressive cardiac dilation (Ang2-tg: 0,55±0,04cm). Furthermore Ang2-tg mice revealed increased heart weight (hw) normalized to body weight (bw) (hw/bw) mg/g. (Ang2-tg: 8,0±1,5, control: 5,2±1,2). Hypertrophy was not observed in Dox or rAAV-Ang1 treated animals. In addition increased HR and reduced MAP shown in Ang2-tg-mice (HR: 615±43bpm, MAP: 84±3mmHg) normalized in Dox-treated (HR: 542±69bpm, MAP:102±9mmHg) or rAAV-Ang1 transfected animals (HR: 506±62bpm, MAP:94±4mmHg) to control level (HR: 545±36bpm, MAP:95±2mmHg). Invasive data confirmed these findings.
Summary: Our results indicate that prolonged Ang-2 overexpression induces progressive LV-dilation and myocardial dysfunction. The cardiac morphology at 12 wks is reversible, if Ang-2 overexpression is shut off, or antagonised by or Ang-1 upregulation. It is tempting to speculate that Ang-2 affects the vascular system profoundly, forcing reactive dilation and cardiac dysfunction.
Abstract 18239: Evaluation of Right Ventricular Function in Patients Undergoing Mitraclip Implantation
Authors: Di Bello Vitantonio , Giannini Cristina , De Carlo Marco , Guarracino Fabio , Pieroni Andrea , Donati Francesca , Minuti Erica , Petronio Anna S 
Published: April 2024

Background: Patients with severe mitral regurgitation (MR) at high surgical risk can undergo percutaneous mitral valve repair by Mitraclip device implantation, yielding good results in terms of quality of life, MR reduction and improvement of left ventricular (LV) function. Our aim was to assess the changes in right ventricular (RV) function after Mitraclip implantation.
Methods: Forty consecutive patients affected by severe symptomatic MR underwent clinical evaluation and echocardiographic assessment before Mitraclip implantation and during follow-up at 1, 3 and 6 months.
Results: The mean age of patients was 75.8±7.5 years, 57.5% (n=23) were male with a mean logistic EuroSCORE of 32.2%±26.3 and a mean LV ejection fraction (EF%) of 38±11. All patients were symptomatic with 36 (90.0%) in NYHA classIII-IV. Thirty-one patients (77.5%) had functional MR, while 7 (22.5%) had a degenerative MR. Acute device success of implantation was achieved in all patients. One clip was placed in 29 patients (72.5%) while 2 clips were deployed in 11 patients (27.5%). Overall mortality was: 0% in-hospital, 2.9% at 1 month, and 14.7% at 1 year follow-up. We didn’t find significant changes in all others RV parameters. Furthermore no differences in RV function changes were present between degenerative and functional MR groups. A significant mild correlation was found between the improvement of NYHA class and the improvement of RV TDI S’ wave at six month follow-up (r=-0.38, p =0.04).
Conclusion: MitraClip implantation has induced a significant reduction of left ventricular volume overload. The concomitant reduction of left ventricular filling pressure, reflected nearly immediately on clinical profile and on hemodynamics of the right sections. In fact, since the first month of follow up, we observed both a significant reduction of estimated pulmonary artery systolic pressure and a significant increase of longitudinal RV systolic function as shown by the increase of TAPSE and RV S’TDI.
Abstract 185: Whole Body Periodic Acceleration (pGz) in Mice Increases Antioxidant Enzymes in the Heart
Authors: Uryash Arkady , Bassuk Jorge , Kurlansky Paul , Lopez-Padrino Jose R , Adams Jose A 
Published: April 2024

BACKGROUND: Mild to moderate exercise produces cardio and neuroprotection. Exercise increases pulsatile shear stress that provide several cytoprotective and signaling substances from muscle and endothelium. Some beneficial effects of exercise on cytoprotection are derived from increased antioxidant capacity. pGz is a passive exercise strategy that moves the body in a sinusoidal head to foot motion, adding pulses to the circulation thereby increasing pulsatile, cyclical shear stress to the endothelium. pGz activates the PI3/Akt eNOS pathway and increases release of eNO and its enzyme (eNOS), and other cytoprotective signaling and substances, and decreases reperfusion injury. Optimum frequency of pGz has been established in our laboratory for various animal species and humans. We tested the hypothesis that repeated exposure to pGz in mice would increase antioxidant enzymes, and determined its time course.
METHODS: Acclimated awake mice (n=48) where exposed to shear stress at f ƒ=480 cpm, Gz ± 3mt/sec 2 (pGz) 1 hr daily sessions of 1, 2, and 4 weeks of pGz. Myocardial tissue was harvested prior to pGz (BL) and 24 hrs after the last pGz treatment for proteins via Western Blot analyses: Glutathioneperoxidase-1(GPX1), Superoxide Dismutase -1 (Cu-Zn SOD), Superoxide Dismutase -2 (mitochondrial or Mn-SOD) and Catalase (Cat) , Protein content was normalized to GAPDH.
RESULTS:One to four weeks of pGz increased GPX1, Cat and SOD1 from BL levels, whereas SOD2 remained unchanged. 4 weeks of pGz increased GPX1, Cat and SOD1, by 110%, 80% and 240% of basal enzyme levels. (Data= mean ± SEM, Figure † p< 0.01 BL vs. 1,2,4 wks)
CONCLUSIONS: One hour daily pGz increases cardiac antioxidant enzymes and may serve as a method to augment endogenous antioxidant capacity, and decrease reperfusion injury.
Abstract 18561: Late Restenosis After Treatment of Bifurcation Lesions Using the Two-stent Strategy
Authors: Habara Seiji , Kadota Kazushige , Saito Naoki , Otsuru Suguru , Hasegawa Daiji , Shigemoto Yoshikazu , Tada Takeshi , Tanaka Hiroyuki , Fuku Yasushi , Goto Tsuyoshi , Mitsudo Kazuaki 
Published: April 2024

Purpose: The purpose of this study was to evaluate serial angiographic outcomes in patients with bifurcation lesions that were treated with two DESs.
Methods: From June 2004 to December 2010, 492 consecutive bifurcation lesions were treated with two DESs. We treated 217 lesions using a sirolimus-eluting stent (SES); 58 using a zotarolimus-eluting stent (ZES); 44 using a biolimus-eluting stent (BES); 40 using a everolimus-eluting stent (EES); 19 using a paclitaxel-eluting stent (PES); 66 with SES+BES; 30 with SES+PES; 7 with SES+ZES; 6 with EES+ZES. The bifurcation lesions were located in the left anterior descending coronary artery/diagonal branch (LAD/D) in 178 lesions, left main distal bifurcation (LM) in 192 lesions, left circumflex coronary artery/obtuse marginal branch (LCX/OM) in 65 lesions and right coronary artery (RCA) distal bifurcation in 57 lesions. The T-stenting technique was used to treat 251 bifurcation lesions, and the culotte stenting technique was used to treat 241 lesions. Angiographic follow-up was performed routinely 8 and 20 months after a successful procedure. Angiographic outcomes were compared between the T-stenting technique and the culotte stenting technique.
Results: Of 492 lesions, 407 (83%) underwent 8-month follow-up angiography. The incidence of binary restenosis at 8-month follow-up was 22.8% (45/197) for the culotte stenting technique and 19.5% (41/210) for the T-stenting technique (p=0.5). The incidence of target lesion revascularization at 8-month follow-up was 12.2% (24/197) for the culotte stenting technique and 11.0% (23/210) for the T-stenting technique (p=0.8). Twenty-month follow-up angiography was performed in 297 lesions (78% of lesions without restenosis at 8-month follow-up angiography). Late restenosis was observed in 17 lesions (11%) with the T-stenting technique and in 5 lesions (3%) with the culotte stenting technique (p=0.014). The incidence of target lesion revascularization at 20-month follow-up was 1.4% (2/145) for the culotte stenting technique and 6.7% (10/152) for the T-stenting technique (p=0.035).
Conclusions: The stenting technique affects the outcomes in patients with bifurcation lesions that are treated with two DESs.
Abstract 18769: Is Conservative Treatment Justified in Marfan Syndrome Patients with Non-Complicated Acute Type B Aortic Dissection? Insights from the International Registry of Acute Aortic Dissection
Authors: Gilon Dan , Pyeritz Reed E , Evangelista Arturo , O'Gara Patrick , Harris Kevin M , Braverman Alan C , Peterson Mark D , Voehringer Matthias , Suzuki Toru , Conklin Lori D , Montgomery Daniel G , Isselbacher Eric M , Nienaber Christoph A , Eagle Kim A , Korach Amit 
Published: April 2024

Introduction: Conservative treatment is the treatment of choice in patients (pts) with non- complicated acute type B aortic dissection (TBAAD). This strategy has not been validated in patients with Marfan Syndrome (MFS) presenting with non-complicated TBAAD.
Methods: Our study evaluated 586 medically managed patients with non-complicated TBAAD enrolled in IRAD between 1996 and 2011. The patients were divided into groups based on the presence (N=15, 2.6%) or absence (N=571, 97.4%) of MFS. Categorical variables were analyzed using chi-square test and Fischer’s exact test where applicable. Continuous variables were analyzed using student’s t-test for normally distributed data, and test of medians for non-normally distributed data.
Results: The mean age was significantly lower for MFS patients (41.3±9.4 years vs 65±13.5 years [p<0.001]). Significantly more patients without MFS had history of hypertension (61.5% vs 40% [p<0.001]). Additionally, those with MFS had significantly higher incidence of prior aortic dissection (64.3% vs 5.8% [p<0.001]), and family history of aortic disease (75% vs 9.5% [p<0.001]). Significantly more non-MFS patients presented with hypertension (70% vs 33.3% [p<0.008]). Abdominal vessels involvement was more frequent in patients with MFS (53.3% vs 22.8% [p=0.011]). During the hospitalization, more patients with MFS had extension of their dissection (20% vs 4% [p=0.024]). None of the patients with MFS died during the index hospitalization, nor did they have new neurological or visceral ischemia. Kaplan-Meyer survival curve showed no significant difference in survival between the two groups from admission to five years follow-up.
Conclusion: The presence of dissection extension in patients with MFS warrants special in-hospital attention. However, our results indicate that, similar to patients without MFS, conservative treatment may be safe in Marfan Syndrome patients presenting with non-complicated acute type B aortic dissection. Given the limited study population, more research is needed to definitively analyze whether non-complicated TBAAD MFS patients would benefit from conservative versus more aggressive dissection management.
Abstract 19032: Performance of Euroscore I, Euroscore II and STS Score for Risk Stratification of Patients Undergoing Transcatheter Aortic Valve Replacement
Authors: D'Onofrio Augusto , Gasparetto Valeria , Rizzoli Giulio , Napodano Massimo , Tarantini Giuseppe , Bianco Roberto , Tessari Chiara , Isabella Giambattista , Gerosa Gino 
Published: April 2024

Purpose: Objective of this single center study was to assess and compare the performance of logistic Euroscore I (ES I), logistic Euroscore II (ES II) and the Society of Thoracic Surgeons (STS) mortality score for risk stratification of patients undergoing transcatheter aortic valve replacement (TAVR).
Methods: We analyzed data of 235 consecutive patients who underwent TAVR from June 2007 through January 2011. We calculated STS, ES1 and ES2 of each patient. Performance of the risk scores was evaluated by means of ROC curves. A logistic multivariable analysis was performed including confounding factors (age, sex) and access: percutaneous (trans-femoral and trans-subclavian) vs. surgical (trans-apical and trans-aortic) TAVI.
Results: Surgical and percutaneous TAVI were performed in 78 (33.2%) and 157 (66.8%) patients, respectively. Mean age was 80.5 ± 6.6 years. Median ES1, ES2 and STS scores were: 17.6%, 5.4% and 6.8% respectively. Thirty-day mortality was 4.3%, the incidence of combined safety events, according to VARC definitions, was 17%. The area under the ROC curve (AUC) for thirty-day mortality was 0.68, 0.66 and 0.60 for ES1, ES2 and STS, respectively (p=0.79). The AUC for combined safety events was 0.57, 0.60 and 0.57 for ES1, ES2 and STS, respectively (p=0.71). After correction for age, sex and approach the AUC for thirty-day mortality was 0.84, 0.75 and 0.74 for ES I, ES II and STS scores, respectively while the AUC for combined safety events was 0.68, 0.66 and 0.65 for ES I, ES II and STS scores, respectively. ES2 and STS performed better in predicting thirty-day mortality in surgical cases (0.75 and 0.74) while ES1 performed better in percutaneous cases (0.76).
Conclusion: According to our analysis, in patients undergoing TAVR, ES1, ES2 and STS scores for thirty-day mortality and for combined safety events provide similar but poor performance (less than 0.75). After correction for confounding factors and approach, ES1 was the only that showed AUC greater than 0.75.
Abstract 19050: Does Type of Culprit Lesion Matter in Patients with Acute Coronary Syndrome and Prior Coronary Artery Bypass Graft Surgery Undergoing Percutaneous Coronary Intervention?
Authors: Harskamp Ralf E , Beijk Marcel A , Damman Peter E , Tijssen Jan G , Krucoff Mitchell W , Lopes Renato D , de Winter Robbert J 
Published: April 2024

Background: Acute coronary syndrome (ACS) in patients with prior coronary artery bypass graft (CABG) surgery may be due to graft failure or progression of native coronary artery disease. We studied whether the culprit lesion (graft vs. native) is associated with differences in hospital and long-term outcomes.
Methods: We included ACS patients with prior CABG who underwent percutaneous coronary intervention (PCI) of >=1 lesion at the Academic Medical Center - University of Amsterdam between 1998 and 2008. The primary outcome was 5-year mortality and the secondary outcome was a composite of in-hospital death, myocardial infarction, need-for-revascularization and stroke. Kaplan-Meier estimates were used to compare 5-year mortality between patients with graft vs. native culprit lesions. Predictors for 5-year mortality were identified using multivariable Cox proportional hazards modeling with backwards variable selection. Logistic regression was used to assess predictors for in-hospital outcomes.
Results: Overall, 270 patients were included, of which 146 (54.1%) had a graft culprit lesion. Mean age was 70 (SD=9.5yrs), 21.9% were women. Multi-vessel PCI was performed in 50 (18.5%) patients. 5-year mortality was similar following graft versus native culprit lesion PCI (41.3% vs. 36.4%, HR:1.16, 95%-CI:0.73-1.84, p=0.52). In-hospital death, MI, need-for-revascularization and/or stroke was also comparable (16.4% vs. 13.7%, HR:1.24 (95%-CI:0.63-2.43), p=0.53). Similar results were seen after adjusting for important covariates. Older age, lack of prior aspirin use, and cardiogenic shock were independently associated with worse clinical outcomes.
Conclusion: Type of culprit lesion (either native or graft) in patients presenting with ACS and prior CABG surgery was not associated with in-hospital or long-term clinical outcomes. Larger studies to validate our findings are warranted.
Abstract 19127: First Simultaneous Assessment of the Effects of Fish Oil Supplementation on Lipid and Thrombogenicity Profiles
Authors: Bliden Kevin , Singla Anand , Tantry Udaya , Jeong Young-Hoon , Ens Gordon , Gurbel Paul A 
Published: April 2024

Background: Fish Oil supplementation may have anti-atherosclerotic effects by reducing triglycerides, improving endothelial function, and reducing inflammation. However, inconsistent results have been reported on the effects of fish oil on platelet function. We aimed to determine if fish oil supplementation reduced the atherothrombotic risk profile by measuring lipids and thrombogenic factors simultaneously .

Methods: Patients with suspected coronary artery disease with (n=79) and without (n=324) fish oil supplementation were enrolled in the Multi-Analyte, Thrombogenic, and Genetic Markers of Atheroclerosis (MAGMA) study. The lipid profile was determined by vertical density gradient ultracentrifugation technique, and thrombogenicity by thrombelastography immediately prior to elective coronary angiography. Urinary 11-dehydrothromboxane B
2
and AtherOx were performed by immunoassay. ADP and collagen-induced platelet aggregation were measured in aspirin+ clopidogrel- treated patients.

Results: Baseline demographics and cardiac risk factors were similar between groups. Fish oil supplementation was associated with significantly lower triglycerides, VLDL, remnant lipoproteins, and AtherOx levels and increased HDL levels (p<0.05). Among patients on aspirin + clopidogrel therapy, fish oil supplementation was associated with lower collagen-induced platelet aggregation (p=0.05, Table).
Conclusion: This is the first study to simultaneously examine the influence of fish oil supplementation on lipid and thrombogenicity profiles. Our study supports prior evidence of an improved lipid profile and suggests an enhancement of the anti-platelet effects of DAPT. Prospective studies are needed to determine the contribution of each of these effects of fish oil supplementation on thrombotic event occurrence.